Abstract
Glutamate is the most abundant excitatory neurotransmitter in the brain and the ionotropic NMDA receptor is one of the major classes of its receptors, thought to play an important role in schizophrenia and mood disorders. The current systematic review summarized the evidence concerning the involvement of NMDA receptors in the pathophysiology of bipolar disorder. Genetic studies point to the genes encoding the NMDA 1, 2A and 2B subunits while neuropathological studies suggest a possible region specific decrease in the density of NMDA receptor and more consistently a reduced NMDA-mediated glutamatergic activity in patients with bipolar disorder in the frame of slower NMDA kinetics because of lower contribution of NR2A subunits. However the literature is poor and incomplete; future research is necessary to elucidate the mechanisms underlying bipolar disorder and its specific relationship to a possible NMDA malfunction and to explore the possibility of developing novel therapeutic agents.
Keywords: NMDA, glutamate, excitatory aminoacids, bipolar disorder, lithium, neurotransmitter, ionotropic NMDA receptor, schizophrenia, mood disorders, glutamatergic activity
Current Pharmaceutical Design
Title:The Possible Involvement of NMDA Glutamate Receptor in the Etiopathogenesis of Bipolar Disorder
Volume: 18 Issue: 12
Author(s): Konstantinos N. Fountoulakis
Affiliation:
Keywords: NMDA, glutamate, excitatory aminoacids, bipolar disorder, lithium, neurotransmitter, ionotropic NMDA receptor, schizophrenia, mood disorders, glutamatergic activity
Abstract: Glutamate is the most abundant excitatory neurotransmitter in the brain and the ionotropic NMDA receptor is one of the major classes of its receptors, thought to play an important role in schizophrenia and mood disorders. The current systematic review summarized the evidence concerning the involvement of NMDA receptors in the pathophysiology of bipolar disorder. Genetic studies point to the genes encoding the NMDA 1, 2A and 2B subunits while neuropathological studies suggest a possible region specific decrease in the density of NMDA receptor and more consistently a reduced NMDA-mediated glutamatergic activity in patients with bipolar disorder in the frame of slower NMDA kinetics because of lower contribution of NR2A subunits. However the literature is poor and incomplete; future research is necessary to elucidate the mechanisms underlying bipolar disorder and its specific relationship to a possible NMDA malfunction and to explore the possibility of developing novel therapeutic agents.
Export Options
About this article
Cite this article as:
Konstantinos N. Fountoulakis , The Possible Involvement of NMDA Glutamate Receptor in the Etiopathogenesis of Bipolar Disorder , Current Pharmaceutical Design 2012; 18 (12) . https://dx.doi.org/10.2174/138161212799958585
DOI https://dx.doi.org/10.2174/138161212799958585 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Herbal Medicine for Slowing Aging and Aging-associated Conditions: Efficacy, Mechanisms and Safety
Current Vascular Pharmacology Disorders of Consciousness and Pharmaceuticals that Act on Oxygen Based Amino Acid and Monoamine Neurotransmitter Pathways of the Brain
Current Pharmaceutical Design Biomarkers and Future Targets for Development in Amyotrophic Lateral Sclerosis
Current Medicinal Chemistry Potential Role of Rho Kinase Inhibitors in Combating Diabetes-Related Complications Including Diabetic Neuropathy-A Review
Current Diabetes Reviews Recent Research Progress in Natural Bioactive Constituents against Lipid Metabolic Diseases
Current Topics in Medicinal Chemistry Non-Linear Alteration of Serotonin Transport Availability in Posttraumatic Stress Disorder Measured with 4-[<sup>18</sup>F] ADAM Positron Emission Tomography
Current Molecular Imaging (Discontinued) Neurotoxicity of Engineered Nanoparticles from Metals
CNS & Neurological Disorders - Drug Targets The Fragile X Family of Disorders: A Model for Autism and Targeted Treatments
Current Pediatric Reviews Distribution of Synthetic Cannabinoids JWH-210, RCS-4 and Δ 9-Tetrahydrocannabinol After Intravenous Administration to Pigs
Current Neuropharmacology Cocaine and HIV-1 Interplay in CNS: Cellular and Molecular Mechanisms
Current HIV Research Implication of Rho GTPases in Neurodegenerative Diseases
Current Drug Targets Mechanistic Approach to Understanding Psychosis Risk in Velocardiofacial Syndrome
Current Pediatric Reviews Biomaterial and Stem Cell Interactions: Histological Biocompatibility
Current Stem Cell Research & Therapy Immune-Neuroendocrine Interactions Involving Thymus and Pineal Gland in Stem Cell Therapy of Age-Related Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Neurosteroids and Sporadic Alzheimers Disease
Current Alzheimer Research Impaired DNA Damage Repair as a Common Feature of Neurodegenerative Diseases and Psychiatric Disorders
Current Molecular Medicine Mitochondria: A Target for Neuroprotective Interventions in Cerebral Ischemia-Reperfusion
Current Pharmaceutical Design In Vivo Experimental Models of Epilepsy
Central Nervous System Agents in Medicinal Chemistry Neuroprotective Effects of Drug-Induced Therapeutic Hypothermia in Central Nervous System Diseases
Current Drug Targets VEGF Mediates ApoE4-Induced Neovascularization and Synaptic Pathology in the Choroid and Retina
Current Alzheimer Research